ASCENDE-RT 15-Year Update: No Survival Benefit, But Borderline Signal for Reduced Deaths
The ASCENDE-RT trial, a 15-year study evaluating the long-term efficacy of Roche (SIX: ROG)‘s atezolizumab in treating non-small cell lung cancer (NSCLC), found no statistically significant overall survival benefit—despite a ... Read More